<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02284737</url>
  </required_header>
  <id_info>
    <org_study_id>FirstNanjingMU</org_study_id>
    <nct_id>NCT02284737</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH</brief_title>
  <acronym>PADN-PAH</acronym>
  <official_title>A Prospective, Multi-center, Randomized Control Trial to Investigate the Efficacy of Pulmonary Artery Denervation to Improved Functional Capacity and Hemodynamics in Patients With Pulmonary Artery Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary arterial hypertension (PAH) is characterized by premature death mainly because of
      progressive and severe right ventricular failure. Target drugs are reported to be associated
      with significant improvement of clinical outcome for PAH patients. However, previous studies
      using those target drugs focused on the change of 6-minute walk distance (6MWD) and or
      hemodynamic responses. As 6MWD has weak correlation with clinical outcome (time to clinical
      worsening, TTCW), benefits from target drugs for PAH patients are not clear. We previously
      reported the safety and efficacy of pulmonary artery denervation (PADN) for treatment of PAH
      patients who were unresponsive to target drugs. Hence, we design the randomized study to
      identify the effect of PADN on PAH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study is designed as a multicenter, randomized and prospective study aiming to
      compare the effect of PADN on PAH patients. Based on the previous studies, the rate of
      pulmonary arterial hypertension (PAH)-related event was around 30% after 6-month treatment
      using target drugs. And our previous data showed that this PAH-related event at 6-month after
      PADN procedure was 15%. As a result, a total of 270 PAH patients was required, with 135
      patients/per group at a ratio of 1:1 randomization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2014</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary artery hypertension (PAH)- related events</measure>
    <time_frame>Baseline to month 6</time_frame>
    <description>Including all-cause death, lung transplantation, atrial septostomy, worsening of PAH, initiation of treatment with intravenous or subcutaneous prostacyclin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-minute walk distance</measure>
    <time_frame>Baseline to month 6</time_frame>
    <description>The 6-minute walk distance (6MWD) test was conducted according to the American Thoracic Society guidelines (ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166(1):111-117.).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary arterial pressure</measure>
    <time_frame>Baseline to month 6</time_frame>
    <description>Pulmonary arterial pressure was obtained with a 7-F flow-directed Swan-Ganz catheter at end-expiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right atrial pressure</measure>
    <time_frame>Baseline to month 6</time_frame>
    <description>Right atrial pressure was obtained with a 7-F flow-directed Swan-Ganz catheter at end-expiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Vascular Resistance</measure>
    <time_frame>Baseline to month 6</time_frame>
    <description>PVR=[mean pulmonary arterial pressure-pulmonary artery occlusion pressure] / cardiac output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>Baseline to month 6</time_frame>
    <description>The amount of blood the heart pumps through the circulatory system in a minute. Measured by right heart catheterization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trans-pulmonary pressure gradient</measure>
    <time_frame>Baseline to month 6</time_frame>
    <description>The transpulmonary pressure gradient (TPG), defined by the difference between mean pulmonary arterial pressure (P(pa)) and left atrial pressure (P(la).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic pressure gradient</measure>
    <time_frame>Baseline to month 6</time_frame>
    <description>The diastolic pressure gradient (DPG), defined by the difference between mean pulmonary arterial pressure and PA occlusion pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary arterial compliance</measure>
    <time_frame>Baseline to month 6</time_frame>
    <description>Pulmonary arterial compliance was obtained with a 7-F flow-directed Swan-Ganz catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg Dyspnea Index</measure>
    <time_frame>Baseline to month 6</time_frame>
    <description>Borg Dyspnea Index is a measure of perceived shortness of breath: 0 units on a scale (none) to 10 units on a scale (maximum breathlessness).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organization (WHO) Functional Class</measure>
    <time_frame>Baseline to month 6</time_frame>
    <description>WHO Classes: I) pulmonary hypertension (PH); ordinary physical activity not limited or causes increased dyspnea, fatigue, chest pain, or presyncope. II) PH; ordinary physical activity mildly limited and causes increased dyspnea, fatigue, chest pain, or presyncope; comfortable at rest. III) PH; physical activity markedly limited and less than ordinary physical activity causes increased dyspnea, fatigue, chest pain, or presyncope; comfortable at rest. IV) PH; physical activity causes symptoms; signs of right heart failure; dyspnea/fatigue possible at rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York functional class</measure>
    <time_frame>Baseline to month 6</time_frame>
    <description>NYHA Classes: I) Patients with no limitation of activities; they suffer no symptoms from ordinary activities. II) Patients with slight, mild limitation of activity; they are comfortable with rest or with mild exertion. III) Patients with marked limitation of activity; they are comfortable at rest. IV) Patients who should be at complete rest, confined to bed or chair; any physical activity brings on discomfort and symptoms occur at rest.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pulmonary artery perforation</measure>
    <time_frame>During PADN procedure</time_frame>
    <description>Number of Participants with pulmonary artery perforation</description>
  </other_outcome>
  <other_outcome>
    <measure>Pulmonary embolism</measure>
    <time_frame>6 months</time_frame>
    <description>PE is classified by suspected and fatal ones. Suspected PE is defined as one of the following: 1) new intra-luminal filling defect on CT scan, MRI scan, or pulmonary angiogram; 2)new perfusion defect of at least 75% on V/Q lung scan; and 3) inconclusive spiral CT, pulmonary angiography or lung scan with demonstration of deep vein thrombosis in the lower extremities by venography. Fatal PE is PE based on objective diagnostic testing or autopsy or death not attributed to a documented cause and for which deep vein thrombosis/PE cannot be ruled out.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>PADN + sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham PADN + sildenafil</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The radiofrequency ablation catheter placed, no ablations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PADN</intervention_name>
    <description>Contrast pulmonary artery angiography is performed to localize the pulmonary artery bifurcation level and to calculate the PA diameter. Once the anatomy is deemed acceptable, the radiofrequency ablation catheter is introduced into the distal bifurcation area of the main PA. The catheter is then maneuvered within the PA to allow energy delivery to ensure that the electrodes are tightly in contact with the endovascular surface. Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.</description>
    <arm_group_label>PADN + sildenafil</arm_group_label>
    <other_name>Pulmonary artery denervation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sham PADN</intervention_name>
    <description>The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.</description>
    <arm_group_label>sham PADN + sildenafil</arm_group_label>
    <other_name>sham pulmonary artery denervation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Participants initially received 5 mg tadalafil for the first 2 weeks in the two groups. The tadalafil dose may have been up titrated to 40 mg after 2 weeks, with maximum effects being obtained. The up titrated of tadalafil to 40 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.</description>
    <arm_group_label>PADN + sildenafil</arm_group_label>
    <arm_group_label>sham PADN + sildenafil</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures;

          -  Men and women 18 years and older;

          -  Group I PAH, defined as a mPAPâ‰¥25mmHg, PCWP&lt;15mmHg and PVR[The PVR
             =(mPAP-PCWP)/CO]&gt;3.0 Woods unit.

        Exclusion Criteria:

        General exclusion criteria:

          -  Pregnancy and breast feeding mother;

          -  Estimated life expectancy &lt;12 months;

          -  Scheduled major surgery in the next 6 months;

          -  Inability to follow the protocol and comply with follow-up requirements or any other
             reason that the investigator feels would place the patient at increased risk;

          -  Previous enrolment in this study or treatment with an investigational drug or device
             under another study protocol in the past 30 days.

        Procedural exclusion criteria:

          -  WHO group II, III, IV, V PH

          -  Severe Renal dysfunction (Ccr&lt;30 ml/min)

          -  Blood platelet count&lt;100,000/L

          -  Expected life span&lt;6-month

          -  Systematical inflammation

          -  Malignant cancer(s)

          -  Tricuspid valve stenosis, Supra-pulmonary valve stenosis

          -  Allergic to studied drugs or metal materials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shao-Liang Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hang Zhang, MD</last_name>
    <phone>+86-25-52208048</phone>
    <email>chmengx@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Kan, MBBS</last_name>
    <phone>+86-25-52271341</phone>
    <email>kanjing@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaoliang Chen, MD</last_name>
      <phone>+86 13605157029</phone>
      <email>chmengx@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Hang zhang, MD</last_name>
      <phone>+86 13951922158</phone>
      <email>dxh_nari@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T, Stone GW. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol. 2013 Sep 17;62(12):1092-1100. doi: 10.1016/j.jacc.2013.05.075. Epub 2013 Jul 10.</citation>
    <PMID>23850902</PMID>
  </reference>
  <reference>
    <citation>Chen SL, Zhang YJ, Zhou L, Xie DJ, Zhang FF, Jia HB, Wong SS, Kwan TW. Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo. EuroIntervention. 2013 Jun 22;9(2):269-76. doi: 10.4244/EIJV9I2A43.</citation>
    <PMID>23466961</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2014</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Shaoliang Chen</investigator_full_name>
    <investigator_title>Vice President</investigator_title>
  </responsible_party>
  <keyword>Pulmonary arterial hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

